InvestSMART

Cynata Therapeutics Limited (ASX: CYP) - Announcements

- Current share price for CYP : $0.012

ASX company news and announcements for Cynata Therapeutics Limited (CYP) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Cynata Therapeutics Limited (CYP) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Cynata Therapeutics Limited (CYP), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Cynata Therapeutics Limited (CYP)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$3 Appendix 3Y-John Chiplin 17 May 2017 3:17PM $0.500 $0.012 fallen by 97.60%
$3 Treatment Commences in Cynata's World First Clinical Trial 16 May 2017 9:49AM $0.570 $0.012 fallen by 97.89%
$3 Trading Halt 15 May 2017 9:40AM $0.570 $0.012 fallen by 97.89%
$3 Shaw & Partners Initiates Cynata Research Coverage 8 May 2017 9:38AM $0.440 $0.012 fallen by 97.27%
$3 Appendix 3Y-Paul Wotton 8 May 2017 9:12AM $0.440 $0.012 fallen by 97.27%
$3 Cyanta Presentation & Webcast 4 May 2017 9:26AM $0.400 $0.012 fallen by 97%
$3 Appendix 3Y-Stewart Washer 3 May 2017 2:42PM $0.425 $0.012 fallen by 97.18%
$3 March 2017 Quarterly Report 26 Apr 2017 4:31PM $0.470 $0.012 fallen by 97.45%
$3 Cynata Advances to Pre-IND Meeting with US FDA 19 Apr 2017 9:06AM $0.475 $0.012 fallen by 97.47%
$3 CYP Files for New Patent for Oncology Applications 12 Apr 2017 9:50AM $0.530 $0.012 fallen by 97.74%
$3 CYP in Collaboration on Acute Respiratory Distress Syndrome 11 Apr 2017 9:34AM $0.480 $0.012 fallen by 97.50%
$3 Appendix 3Y-Ross Macdonald 3 Apr 2017 12:21AM $0.460 $0.012 fallen by 97.39%
$3 Cynata Partner apceth GmbH & Co Completes Cymerus Evaluation 31 Mar 2017 9:20AM $0.570 $0.012 fallen by 97.89%
$3 Proactive Investor Conference Presentation 10 Mar 2017 3:06PM $0.485 $0.012 fallen by 97.53%
$3 CYP Advances Development of Cymerus for Treatment of Asthma 2 Mar 2017 9:41AM $0.500 $0.012 fallen by 97.60%
$3 Dr Paul Wotton Appointment as Chairman of Cynata 28 Feb 2017 9:25AM $0.530 $0.012 fallen by 97.74%
$3 Appendix 4D & Half-Year Financial Statements 27 Feb 2017 8:27PM $0.530 $0.012 fallen by 97.74%
$3 Change in substantial holding 24 Feb 2017 7:48PM $0.550 $0.012 fallen by 97.82%
$3 Becoming a substantial holder 20 Feb 2017 9:47AM $0.615 $0.012 fallen by 98.05%
$3 Final GvHD Preclinical Report Confirms Treatment Benefit 6 Feb 2017 10:38AM $0.600 $0.012 fallen by 98%
$3 Positive Preliminary Data from Preclinical HeartAttack Study 2 Feb 2017 9:44AM $0.580 $0.012 fallen by 97.93%
$3 Notice Under Section 708A 30 Jan 2017 5:15PM $0.610 $0.012 fallen by 98.03%
$3 Information Required Under ASX Listing Rule 3.10.5A 30 Jan 2017 5:14PM $0.610 $0.012 fallen by 98.03%
$3 Appendix 3B-Completion of Placement 30 Jan 2017 5:11PM $0.610 $0.012 fallen by 98.03%
$3 Notice Under Section 708A 25 Jan 2017 6:29PM $0.645 $0.012 fallen by 98.14%

576 - 600 of 699 results

Page 24 of 28

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.